Home › Compare › ESKKF vs ABBV
ESKKF yields 581.56% · ABBV yields 3.06%● Live data
📍 ESKKF pulled ahead of the other in Year 1
Combined, ESKKF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ESKKF + ABBV for your $10,000?
Etherstack plc, a wireless technology company, engages in licensing mission critical radio technologies to equipment manufacturers and network operators Australia and internationally. Its technology enables push-to-talk (PTT) communications; and advanced digital land mobile radio (LMR), and cellular and satellite networks. The company offers a range of cryptographic solutions, including P25 Security Suite unites AES/DES P25 encryption engine with P25 key fill device (KFD) support for complete P25 subscriber encryption; P25 key management facility; P25 security dongles; and FIPS 140-2 Cryptographic Module, a single-board security device that implements APCO P25 encryption, decryption, and key management and storage services in conformance with FIPS140-2 standards. It also provides defense waveforms, such as technology licensing and transfer, and specialist services; waveform heritage; waveform test and development environment; outsource your risks; and reconfiguration and framework architecture standards. In addition, the company offers LMR network building blocks; APCO P25, dPMR, DMR, MPT1327, and TETRA wireless communications protocol stacks; and tactical and satellite solutions comprising P25 tactical repeaters and IVX PTT IP radio. It serves public safety, defense, utilities, transportation, and resource sectors. The company was formerly known as MM&S (5698) plc and changed its name to Etherstack plc in May 2012. Etherstack plc was incorporated in 2012 and is based in Chippendale, Australia.
Full ESKKF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.